

Supplemental Data to:

Clopidogrel carboxylic acid glucuronidation is mediated mainly by UGT2B7, UGT2B4 and UGT2B17: Implications for pharmacogenetics and drug-drug interactions

Helinä Kahma, Anne M. Filppula, Mikko Neuvonen, E. Katriina Tarkiainen, Aleksi Tornio, Mikko T. Holmberg, Matti K. Itkonen, Moshe Finel, Pertti J. Neuvonen, Mikko Niemi and Janne T. Backman

Drug Metabolism and Disposition

Supplementary Table 1. Characteristics of the eight clinical studies that were included in the analysis of the possible associations between UGT genotypes and the pharmacokinetic variables of clopidogrel carboxylic acid.

Reference	Primary study type	Role of clopidogrel	Dose (mg)	Sex (f/m)	Age (years)	Weight (kg)	BMI (kg/m ²)
Holmberg et al., 2014	Crossover DDI study	Victim	600	6/7	22 ± 1	68 ± 10	22 ± 2
Itkonen et al., 2015	Crossover DDI study	Perpetrator	300	3/8	22 ± 2	74 ± 9	23 ± 2
Itkonen et al., 2016	Crossover DDI study	Perpetrator	300	4/4	25 ± 6	68 ± 11	22 ± 2
Tarkiainen et al., 2015	Genotype panel study	Substrate	600	8/13	25 ± 4	72 ± 14	23 ± 3
Tornio et al., 2014	Crossover DDI study	Perpetrator	300	4/3	24 ± 3	63 ± 9	21 ± 2
Holmberg et al., unpublished data	Genotype panel study	Substrate	600	11/12	25 ± 5	72 ± 13	23 ± 3
Itkonen et al., unpublished data I	Crossover DDI study	Perpetrator	300	6/5	23 ± 2	71 ± 12	23 ± 2
Itkonen et al., unpublished data II	Crossover DDI study	Perpetrator	300	7/5	25 ± 4	74 ± 17	24 ± 3
Total				49/57	24 ± 4	71 ± 13	23 ± 3

Data are presented as mean ± S.D., unless otherwise indicated. BMI, body mass index; DDI, drug-drug interaction; f, females; m, males; UGT, UDP-glucuronosyltransferase.

Supplemental References

Holmberg MT, Tornio A, Neuvonen M, Neuvonen PJ, Backman JT and Niemi M (2014) Grapefruit juice inhibits the metabolic activation of clopidogrel. *Clin Pharmacol Ther* **95**:307-13.

Itkonen MK, Tornio A, Neuvonen M, Neuvonen PJ, Niemi M and Backman JT (2015) Clopidogrel has no clinically meaningful effect on the pharmacokinetics of the organic anion transporting polypeptide 1B1 and cytochrome P450 3A4 substrate simvastatin. *Drug Metab Dispos* **43**:1655-60.

Itkonen MK, Tornio A, Neuvonen M, Neuvonen PJ, Niemi M and Backman JT (2016) Clopidogrel markedly increases plasma concentrations of CYP2C8 substrate pioglitazone. *Drug Metab Dispos* **44**:1364-71.

Tarkiainen EK, Holmberg MT, Tornio A, Neuvonen M, Neuvonen PJ, Backman JT and Niemi M (2015) Carboxylesterase 1 c.428G>A single nucleotide variation increases the antiplatelet effects of clopidogrel by reducing its hydrolysis in humans. *Clin Pharmacol Ther* **97**:650-8.

Tornio A, Filppula AM, Kailari O, Neuvonen M, Nyrönen TH, Tapaninen T, Neuvonen PJ, Niemi M and Backman JT (2014) Glucuronidation converts clopidogrel to a strong time-dependent inhibitor of CYP2C8: a phase II metabolite as a perpetrator of drug-drug interactions. *Clin Pharmacol Ther* **96**:498-507.